Nature Reviews Drug Discovery最新文献

筛选

英文中文

FGF-based drug discovery: advances and challenges 基于fgf的药物发现：进展与挑战

Nature Reviews Drug Discovery Pub Date : 2025-01-28 DOI: 10.1038/s41573-024-01125-w

Gaozhi Chen, Lingfeng Chen, Xiaokun Li, Moosa Mohammadi

{"title":"FGF-based drug discovery: advances and challenges","authors":"Gaozhi Chen, Lingfeng Chen, Xiaokun Li, Moosa Mohammadi","doi":"10.1038/s41573-024-01125-w","DOIUrl":"https://doi.org/10.1038/s41573-024-01125-w","url":null,"abstract":"<p>The fibroblast growth factor (FGF) family comprises 15 paracrine-acting and 3 endocrine-acting polypeptides, which govern a multitude of processes in human development, metabolism and tissue homeostasis. Therapeutic endocrine FGFs have recently advanced in clinical trials, with FGF19 and FGF21-based therapies on the cusp of approval for the treatment of primary sclerosing cholangitis and metabolic syndrome-associated steatohepatitis, respectively. By contrast, while paracrine FGFs were once thought to be promising drug candidates for wound healing, burns, tissue repair and ischaemic ailments based on their potent mitogenic and angiogenic properties, repeated failures in clinical trials have led to the widespread perception that the development of paracrine FGF-based drugs is not feasible. However, the observation that paracrine FGFs can exert FGF hormone-like metabolic activities has restored interest in these FGFs. The recent structural elucidation of the FGF cell surface signalling machinery and the formulation of a new threshold model for FGF signalling specificity have paved the way for therapeutically harnessing paracrine FGFs for the treatment of a range of metabolic diseases.</p>","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The benefits of translating biomedical research at drug discovery institutes 药物研发机构转化生物医学研究的益处

Nature Reviews Drug Discovery Pub Date : 2024-09-26 DOI: 10.1038/d41573-024-00142-z

David J. Huggins, Jonathan Baell, Paul E. Brennan, Alex Burgin, Duncan E. Scott

引用次数: 0

首页上一页